Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This article was retracted on June 1, 2001.
This Article
Right arrow Full Text (PDF)
Right arrow Retraction (v19,p2973)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bezwoda, W. R.
Right arrow Articles by Dansey, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bezwoda, W. R.
Right arrow Articles by Dansey, R. D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 13, 2483-2489, Copyright © 1995 by American Society of Clinical Oncology

ARTICLES

High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial

WR Bezwoda, L Seymour and RD Dansey
Department of Medicine, University of Witwatersrand, South Africa.

PURPOSE: The aims of this study were to compare in a randomized trial the results of high-dose versus conventional-dose chemotherapy as first- line treatment for metastatic breast cancer. The comparison included complete response (CR) rate, duration of response, and duration of survival. PATIENTS AND METHODS: Ninety patients were entered onto a study to compare two cycles of high-dose cyclophosphamide 2.4 g/m2, mitoxantrone 35 to 45 mg/m2, and etoposide (VP16) 2.5 g/m2 (HD-CNV) versus six to eight cycles of conventional-dose cyclophosphamide 600 mg/m2, mitoxantrone 12 mg/m2, and vincristine 1.4 mg/m2 (CNV) as first- line treatment for metastatic breast cancer. The high-dose regimen included either autologous bone marrow or peripheral-blood stem-cell rescue. All 90 patients are assessable. RESULTS: The response rates were significantly different. The overall response rate for HD-CNV was 43 of 45 (95%), with 23 of 45 patients (51%) achieving CR. Twenty-four of 45 patients (53%) who received conventional CNV have responded, with only two patients achieving CR. Both duration of response and duration of survival were significantly longer for patients, who received HD- CNV. Toxicity of the high-dose therapy was moderate in most patients. Grade 2 to 3 mucositis and hematologic suppression that required supportive treatment was universal, but hematologic recovery to a neutrophil count more than 500/microL and platelet count more than 40,000/microL occurred at day 18 (median) after therapy. CONCLUSION: HD- CNV appears to be a promising schedule that results in a significant proportion of CRs and increased survival in patients with metastatic breast cancer.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
P. A. Francis
Surprised by Hope
J. Clin. Oncol., December 20, 2008; 26(36): 6001 - 6002.
[Full Text] [PDF]

Home page
 JCOHome page
M. Crump, S. Gluck, D. Tu, D. Stewart, M. Levine, P. Kirkbride, J. Dancey, S. O'Reilly, T. Shore, S. Couban, et al.
Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16
J. Clin. Oncol., January 1, 2008; 26(1): 37 - 43.
[Abstract] [Full Text] [PDF]

Home page
 Clin TrialsHome page
M. Mayer
Listen to all the voices: an advocate's perspective on early access to investigational therapies
Clinical Trials, April 1, 2006; 3(2): 149 - 153.
[Abstract] [PDF]

Home page
 J. Leukoc. Biol.Home page
A. Bellemare-Pelletier, J. Tremblay, S. Beaulieu, M.-R. Boulassel, J.-P. Routy, B. Massie, R. Lapointe, and J. Thibodeau
HLA-DO transduced in human monocyte-derived dendritic cells modulates MHC class II antigen processing
J. Leukoc. Biol., July 1, 2005; 78(1): 95 - 105.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A.R. Zander, N. Kroger, C. Schmoor, W. Kruger, V. Mobus, N. Frickhofen, B. Metzner, W. Schultze, W.E. Berdel, M. Koenigsmann, et al.
High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Support Compared With Standard-Dose Chemotherapy in Breast Cancer Patients With 10 or More Positive Lymph Nodes: First Results of a Randomized Trial
J. Clin. Oncol., June 15, 2004; 22(12): 2273 - 2283.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Gratwohl, H. Baldomero, B. Horisberger, C. Schmid, J. Passweg, and A. Urbano-Ispizua
Current trends in hematopoietic stem cell transplantation in Europe
Blood, September 18, 2002; 100(7): 2374 - 2386.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
G. Friedel, U. Pastorino, R. J. Ginsberg, P. Goldstraw, M. Johnston, H. Pass, J. B. Putnam, and H. Toomes
Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the international registry of lung metastases
Eur. J. Cardiothorac. Surg., September 1, 2002; 22(3): 335 - 344.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
H G. Welch and J. Mogielnicki
Presumed benefit: lessons from the American experience with marrow transplantation for breast cancer
BMJ, May 4, 2002; 324(7345): 1088 - 1092.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
N. C. Dolan, K. Freund, and J. Walsh
Update in Women's Health
Ann Intern Med, March 19, 2002; 136(6): 453 - 462.
[Full Text] [PDF]

Home page
 JCOHome page
J. R. Gralow and R. B. Livingston
University of Washington High-Dose Cyclophosphamide, Mitoxantrone, and Etoposide Experience in Metastatic Breast Cancer: Unexpected Cardiac Toxicity
J. Clin. Oncol., September 15, 2001; 19(18): 3903 - 3904.
[Full Text] [PDF]

Home page
 Health Aff (Millwood)Home page
M. M. Mello and T. A. Brennan
The Controversy Over High-Dose Chemotherapy With Autologous Bone Marrow Transplant For Breast Cancer
Health Aff., September 1, 2001; 20(5): 101 - 117.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Miura, C. J. Thoburn, E. C. Bright, M. Sommer, S. Lefell, M. Ueda, S. Nakao, and A. D. Hess
Characterization of the T-cell repertoire in autologous graft-versus-host disease (GVHD): evidence for the involvement of antigen-driven T-cell response in the development of autologous GVHD
Blood, August 1, 2001; 98(3): 868 - 876.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. B. Weiss, G. G. Gill, and C. A. Hudis
An On-Site Audit of the South African Trial of High-Dose Chemotherapy for Metastatic Breast Cancer and Associated Publications
J. Clin. Oncol., June 1, 2001; 999(1): 1 - 8.
[Abstract] [Full Text]

Home page
 JCOHome page
RETRACTION
J. Clin. Oncol., June 1, 2001; 999(1): 1-a - 1.
[Full Text]

Home page
 JCOHome page
L. Norton
High-Dose Chemotherapy for Breast Cancer: "How Do You Know?"
J. Clin. Oncol., June 1, 2001; 999(1): 1-b - 2.
[Full Text]

Home page
 JCOHome page
L. Norton
High-Dose Chemotherapy for Breast Cancer: ""How Do You Know?""
J. Clin. Oncol., June 1, 2001; 19(11): 2769 - 2770.
[Full Text] [PDF]

Home page
 JCOHome page
R. B. Weiss, G. G. Gill, and C. A. Hudis
An On-Site Audit of the South African Trial of High-Dose Chemotherapy for Metastatic Breast Cancer and Associated Publications
J. Clin. Oncol., June 1, 2001; 19(11): 2771 - 2777.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
Retraction
J. Clin. Oncol., June 1, 2001; 19(11): 2973 - 2973.
[Full Text] [PDF]

Home page
 JCOHome page
P. L. Zinzani, S. Ascani, P. P. Piccaluga, M. Bendandi, S. Pileri, and S. Tura
Efficacy of rituximab in hairy cell leukemia treatment.
J. Clin. Oncol., November 15, 2000; 18(22): 3875 - 3877.
[Full Text]

Home page
 The OncologistHome page
S. Rodenhuis
The Status of High-Dose Chemotherapy in Breast Cancer
Oncologist, October 1, 2000; 5(5): 369 - 375.
[Abstract] [Full Text]

Home page
 JCOHome page
A. Vickers and P. Christos
Bezwoda: Evidence of Fabrication in Original Article
J. Clin. Oncol., August 15, 2000; 18(15): 2933 - 2933.
[Full Text]

Home page
 J Am Coll CardiolHome page
D. Cardinale, M. T. Sandri, A. Martinoni, A. Tricca LabTech, M. Civelli, G. Lamantia, S. Cinieri, G. Martinelli, C. M. Cipolla, and C. Fiorentini
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
J. Am. Coll. Cardiol., August 1, 2000; 36(2): 517 - 522.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. P. Canellos
The Policing of Clinical Trials
J. Clin. Oncol., June 12, 2000; 18(12): 2353 - 2353.
[Full Text] [PDF]

Home page
 JCOHome page
A. Patnaik, J. MacKinnon, P. Goss, T. Nagy, K. Stewart, A. Keating, and M. Crump
Phase I/II Trial of Cyclophosphamide, Mitoxantrone, and Escalated Doses of Carboplatin Supported by Peripheral-Blood Stem Cells in Women With Metastatic Breast Cancer
J. Clin. Oncol., June 12, 2000; 18(12): 2363 - 2368.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. A. Stadtmauer, A. O'Neill, L. J. Goldstein, P. A. Crilley, K. F. Mangan, J. N. Ingle, I. Brodsky, S. Martino, H. M. Lazarus, J. K. Erban, et al.
Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy plus Autologous Hematopoietic Stem-Cell Transplantation for Metastatic Breast Cancer
N. Engl. J. Med., April 13, 2000; 342(15): 1069 - 1076.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
W. P. Peters, R. D. Dansey, J. L. Klein, and R. D. Baynes
High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation in the Treatment of Breast Cancer
Oncologist, February 1, 2000; 5(1): 1 - 13.
[Abstract] [Full Text]

Home page
 The OncologistHome page
J. O'Shaughnessy
High Dose Chemotherapy for Breast Cancer: Taking Stock
Oncologist, February 1, 2000; 5(1): 14 - 17.
[Full Text]

Home page
 The OncologistHome page
R. B. Weiss
The Randomized Trials of Dose-Intensive Therapy for Breast Cancer: What Do They Mean for Patient Care and Where Do We Go From Here?
Oncologist, December 1, 1999; 4(6): 450 - 458.
[Abstract] [Full Text]

Home page
 JAMAHome page
K. H. Antman, D. F. Heitjan, and G. N. Hortobagyi
High-Dose Chemotherapy for Breast Cancer
JAMA, November 10, 1999; 282(18): 1701 - 1703.
[Full Text] [PDF]

Home page
 JCOHome page
R. Livingston and J. Crowley
Commentary on PBT-1 Study of High-Dose Consolidation Versus Standard Therapy in Metastatic Breast Cancer
J. Clin. Oncol., November 1, 1999; 17(90001): 22 - 24.
[Full Text] [PDF]

Home page
 JCOHome page
G. N. Hortobagyi
High-Dose Chemotherapy for Primary Breast Cancer: Facts Versus Anecdotes
J. Clin. Oncol., November 1, 1999; 17(90001): 25 - 29.
[Full Text] [PDF]

Home page
 JCOHome page
K. H. Antman
Critique of the High-Dose Chemotherapy Studies in Breast Cancer: A Positive Look at the Data
J. Clin. Oncol., November 1, 1999; 17(90001): 30 - 34.
[Full Text] [PDF]

Home page
 JAMAHome page
P. A. Rowlings, S. F. Williams, K. H. Antman, K. K. Fields, J. W. Fay, E. Reed, C. J. Pelz, J. P. Klein, K. A. Sobocinski, M. J. Kennedy, et al.
Factors Correlated With Progression-Free Survival After High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Metastatic Breast Cancer
JAMA, October 13, 1999; 282(14): 1335 - 1343.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
W. J. Gradishar
High-Dose Chemotherapy and Breast Cancer
JAMA, October 13, 1999; 282(14): 1378 - 1380.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. E. Groopman and L. M. Itri
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. A. Rizzieri, J. J. Vredenburgh, R. Jones, M. Ross, E. J. Shpall, A. Hussein, G. Broadwater, D. Berry, W. P. Petros, C. Gilbert, et al.
Prognostic and Predictive Factors for Patients With Metastatic Breast Cancer Undergoing Aggressive Induction Therapy Followed by High-Dose Chemotherapy With Autologous Stem-Cell Support
J. Clin. Oncol., October 1, 1999; 17(10): 3064 - 3074.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Schirrmeister, A. Guhlmann, J. Kotzerke, C. Santjohanser, T. Kuhn, R. Kreienberg, P. Messer, K. Nussle, K. Elsner, G. Glatting, et al.
Early Detection and Accurate Description of Extent of Metastatic Bone Disease in Breast Cancer With Fluoride Ion and Positron Emission Tomography
J. Clin. Oncol., August 1, 1999; 17(8): 2381 - 2381.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Adkins, R. Brown, K. Trinkaus, R. Maziarz, S. Luedke, C. Freytes, B. Needles, D. Wienski, P. Fracasso, T. Pluard, et al.
Outcomes of High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in Stage IIIB Inflammatory Breast Cancer
J. Clin. Oncol., July 1, 1999; 17(7): 2006 - 2006.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Schilder, S. Johnson, J. Gallo, S. Kindsfather, B. Rogers, M. A. Bookman, M. M. Millenson, M. Boente, N. Rosenblum, S. Litwin, et al.
Phase I Trial of Multiple Cycles of High-Dose Chemotherapy Supported by Autologous Peripheral-Blood Stem Cells
J. Clin. Oncol., July 1, 1999; 17(7): 2198 - 2198.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. A. Franklin, J. Glaspy, S. M. Pflaumer, R. B. Jones, L. Hami, C. Martinez, J. R. Murphy, and E. J. Shpall
Incidence of Tumor-Cell Contamination in Leukapheresis Products of Breast Cancer Patients Mobilized With Stem Cell Factor and Granulocyte Colony-Stimulating Factor (G-CSF) or With G-CSF Alone
Blood, July 1, 1999; 94(1): 340 - 347.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Mohr, E. Hilgenfeld, T. Fietz, B. Hoppe, M. Koenigsmann, M. Hoffmann, W. U. Knauf, U. Cassens, W. Sibrowski, J. Kienast, et al.
Efficacy and Safety of Simultaneous Immunomagnetic CD34+ Cell Selection and Breast Cancer Cell Purging in Peripheral Blood Progenitor Cell Samples Used for Hematopoietic Rescue after High-Dose Therapy
Clin. Cancer Res., May 1, 1999; 5(5): 1035 - 1040.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Somlo, I. Sniecinski, A. ter Veer, J. Longmate, G. Knutson, S. Vuk-Pavlovic, R. Bhatia, W. Chow, L. Leong, R. Morgan, et al.
Recombinant Human Thrombopoietin in Combination With Granulocyte Colony-Stimulating Factor Enhances Mobilization of Peripheral Blood Progenitor Cells, Increases Peripheral Blood Platelet Concentration, and Accelerates Hematopoietic Recovery Following High-Dose Chemotherapy
Blood, May 1, 1999; 93(9): 2798 - 2806.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Kouroussis, N. Androulakis, S. Kakolyris, J. Souglakos, T. Kotsakis, D. Mavroudis, K. Katsogridakis, N. Vardakis, D. Hatzidaki, G. Samonis, et al.
Dose-Escalation Study of Docetaxel in Combination With Mitoxantrone as First-Line Treatment in Patients With Metastatic Breast Cancer
J. Clin. Oncol., March 1, 1999; 17(3): 862 - 862.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. L. Carter, L. B. Marks, J. M. Bean, G. Broadwater, A. Hussein, J. J. Vredenburgh, W. P. Peters, and L. R. Prosnitz
Impact of Consolidation Radiotherapy in Patients With Advanced Breast Cancer Treated With High-Dose Chemotherapy and Autologous Bone Marrow Rescue
J. Clin. Oncol., March 1, 1999; 17(3): 887 - 887.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. L. Vogel and J.-M. Nabholtz
Monotherapy of Metastatic Breast Cancer: A Review of Newer Agents
Oncologist, February 1, 1999; 4(1): 17 - 33.
[Abstract] [Full Text]

Home page
 BloodHome page
A. Spyridonidis, W. Bernhardt, D. Behringer, G. Kohler, M. Azemar, A. Pflug, and R. Henschler
Proliferation and Survival of Mammary Carcinoma Cells Are Influenced by Culture Conditions Used for Ex Vivo Expansion of CD34+ Blood Progenitor Cells
Blood, January 15, 1999; 93(2): 746 - 755.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. L. Basser, L. B. To, J. P. Collins, C. G. Begley, D. Keefe, J. Cebon, J. Bashford, S. Durrant, J. Szer, D. Kotasek, et al.
Multicycle High-Dose Chemotherapy and Filgrastim-Mobilized Peripheral-Blood Progenitor Cells in Women With High-Risk Stage II or III Breast Cancer: Five-Year Follow-Up
J. Clin. Oncol., January 1, 1999; 17(1): 82 - 82.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. N. Hortobagyi
Treatment of Breast Cancer
N. Engl. J. Med., October 1, 1998; 339(14): 974 - 984.
[Full Text] [PDF]

Home page
 The OncologistHome page
S. Subramanyan and M. J. Kennedy
Breast Cancer: High-Dose Therapy
Oncologist, October 1, 1998; 3(5): 289 - 299.
[Abstract] [Full Text]

Home page
 The OncologistHome page
C.H. Weaver, W. West, L. Schwartzberg, R. Birch, and C.D. Buckner
The Rationale for Performing Autologous Peripheral Blood Stem Cell Transplants in Community Cancer Centers
Oncologist, October 1, 1998; 3(5): 346 - 353.
[Abstract] [Full Text]

Home page
 BloodHome page
T. Guillaume, D. B. Rubinstein, and M. Symann
Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation
Blood, September 1, 1998; 92(5): 1471 - 1490.
[Full Text] [PDF]

Home page
 BloodHome page
A. Spyridonidis, M. Schmidt, W. Bernhardt, A. Papadimitriou, M. Azemar, W. Wels, B. Groner, and R. Henschler
Purging of Mammary Carcinoma Cells During Ex Vivo Culture of CD34+ Hematopoietic Progenitor Cells With Recombinant Immunotoxins
Blood, March 1, 1998; 91(5): 1820 - 1827.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. Makatsoris and M. V. Seiden
High-Dose Therapy for Ovarian Carcinoma
Oncologist, October 1, 1997; 2(5): 330 - 339.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J.-P. Droz, S. Culine, P. Biron, and A. Kramar
High-Dose Chemotherapy in Adult Solid Tumors and Lymphoproliferative Disorders: The Need for Randomized Trials
Oncologist, April 1, 1997; 2(2): 83 - 93.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L.B. To, D.N. Haylock, P.J. Simmons, and C.A. Juttner
The Biology and Clinical Uses of Blood Stem Cells
Blood, April 1, 1997; 89(7): 2233 - 2258.
[Full Text] [PDF]

Home page
 BloodHome page
A. D. Hess, E. C. Bright, C. Thoburn, G. B. Vogelsang, R. J. Jones, and M. J. Kennedy
Specificity of Effector T Lymphocytes in Autologous Graft-Versus-Host Disease: Role of the Major Histocompatibility Complex Class II Invariant Chain Peptide
Blood, March 15, 1997; 89(6): 2203 - 2209.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. K.W. Lie and L. B. To
Peripheral Blood Stem Cells: Transplantation and Beyond
Oncologist, February 1, 1997; 2(1): 40 - 49.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Smith, J. Abrams, E. L. Trimble, and R. S. Ungerleider
Dose Intensity of Chemotherapy for Childhood Cancers
Oncologist, October 1, 1996; 1(5): 293 - 304.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
Z. S. Pavletic and J. O. Armitage
Bone Marrow Transplantation for Cancer--An Update
Oncologist, June 1, 1996; 1(3): 159 - 168.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
J. S. Partyka
Introduction
Journal of Oncology Pharmacy Practice, January 1, 1996; 2(1_suppl): 2 - 3.
[PDF]

Home page
 JWatch GeneralHome page
HIGH-DOSE CHEMOTHERAPY FOR METASTATIC BREAST CANCER
Journal Watch (General), November 3, 1995; 1995(1103): 2 - 2.
[Full Text]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1995 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online